Genmab | GEN - سرمایه عادی





سرمایه عادی تغییر دادن تاریخ
Agios Pharmaceuticals USD 58.45M 169K 2025-12
Almirall EUR 214.79M 0 2025-12
Amarin USD 20.81M 13K 2025-12
Amgen USD 539M 1000K 2025-12
AstraZeneca USD 1.55B 206K 2025-12
Bayer EUR 982.42M 0 2025-12
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Demant DKK 210.9M 5.18M 2025-12
Exelixis USD 268.1M 2.03M 2025-09
Fresenius Medical Care EUR 279.29M 10.56M 2025-12
Galapagos EUR 65.9M 0 2025-12
Genmab DKK 61.62M 52K 2025-12
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
GN Store Nord DKK 145.61M 458.39M 2025-09
GRIFOLS EUR 680.58M 846K 2025-12
Hikma Pharmaceutical USD 221.89M 181.89M 2025-12
Insmed USD 214.26M 1.67M 2025-12
Lonza CHF 68.64M 0 2025-12
Merck EUR 434.78M 0 2025-12
Novartis USD 1.91B 10.64M 2025-12
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Roche Holding CHF 795.62M 699.54K 2025-12
UCB EUR 190.36M 365.15K 2025-12